Výsledky vyhledávání - "Waleed Shalaby"

Akademický článek

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

Autor: Robin L. Jones, Thomas J. Herzog, Shreyaskumar R. Patel, Margaret von Mehren, Scott M. Schuetze, Brian A. Van Tine, Robert L. Coleman, Roland Knoblauch, Spyros Triantos, Peter Hu, Waleed Shalaby, Tracy McGowan, Bradley J. Monk, George D. Demetri

Publikováno v: Cancer Medicine, Vol 10, Iss 11, Pp 3565-3574 (2021)

Abstract Background As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Card

Externí odkaz: https://doaj.org/article/f437f40c60df4df4949dc5750e11832b

Zobrazit plný text záznamu

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

Autor: Shreyaskumar Patel, Tracy McGowan, Spyros Triantos, Margaret von Mehren, Scott M. Schuetze, Roland Elmar Knoblauch, Waleed Shalaby, Peter Hu, Brian A. Van Tine, Bradley J. Monk, Robert L. Coleman, Thomas J. Herzog, Robin L. Jones, George D. Demetri

Publikováno v: Cancer Medicine, Vol 10, Iss 11, Pp 3565-3574 (2021)
Cancer Medicine

Background As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7391d426cc44ae5b508c00b6d9fc2b18
https://doi.org/10.1002/cam4.3903

Zobrazit plný text záznamu

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer

Autor: Waleed Shalaby, Scott Maul, Bradley J. Monk, Spyros Triantos, George Wang, Roland Elmar Knoblauch, Thomas J. Herzog, Robert L. Coleman, Tracy McGowan

Publikováno v: Gynecologic Oncology. 156:535-544

Objective This phase 3 study aimed to compare overall survival (OS) of women with platinum-sensitive, recurrent ovarian cancer (ROC) treated with third-line trabectedin (T) + pegylated liposomal doxorubicin (PLD) vs. PLD monotherapy. Methods Women wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d41f00216a5105114429433c87eef24
https://doi.org/10.1016/j.ygyno.2019.12.043

Zobrazit plný text záznamu

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin

Autor: Shreyaskumar Patel, Robert G. Maki, Tracy McGowan, Robin L. Jones, George Wang, Roland Elmar Knoblauch, Waleed Shalaby, George D. Demetri, Margaret von Mehren

Publikováno v: Cancer

Background The results of the randomized, phase 3 ET743‐SAR‐3007 trial demonstrated that trabectedin had a significantly longer progression‐free survival (PFS) compared with dacarbazine in patients with advanced leiomyosarcoma/liposarcoma after

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8a7717942d765e32e631dc8f9567b4
http://europepmc.org/articles/PMC6916570

Zobrazit plný text záznamu

Fibroblast growth factor receptor alteration (FGFRa) status and progression outcomes of patients with advanced or metastatic urothelial cancer (mUC)

Autor: Grace L. Lu-Yao, Vittorio Maio, Arlene O. Siefker-Radtke, Albert G. Crawford, Jianjun Gao, Sarah Fleming, Philip S. Rosenberg, Waleed Shalaby, Christopher Gaj, Dina Gifkins

Publikováno v: Journal of Clinical Oncology. 39:4530-4530

4530 Background: FGFRa appear in approximately 15% of cases of mUC. Data on whether FGFRa in mUC have a prognostic impact or predictive benefit for particular treatments have been limited by small sample sizes. The objective of this study was to eval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3795cbb8f9b8bd3c6cbce067d59c83fe
https://doi.org/10.1200/jco.2021.39.15_suppl.4530

Zobrazit plný text záznamu

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

Autor: Scott Maul, Waleed Shalaby, Robert L. Coleman, Tracy McGowan, Bradley J. Monk, Thomas J. Herzog, George Wang, Roland Elmar Knoblauch, Spyros Triantos

Publikováno v: Data in Brief
Data in Brief, Vol 30, Iss, Pp 105465-(2020)

The data presented herein are supplementary to our published primary article “A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e41f45442ab232879d8fe28b8a14204f
https://doi.org/10.1016/j.dib.2020.105465

Zobrazit plný text záznamu

Use of a dynamic disease progression model to estimate prevalence and prognosis for patients with urothelial carcinoma (UC) in the United States (US)

Autor: Kirk Solo, Waleed Shalaby, Xuehua Ke, Arlene O. Siefker-Radtke, Sarah Fleming

Publikováno v: Journal of Clinical Oncology. 38:e19144-e19144

e19144 Background: Quantifying the distribution and prognosis of patients with UC as a function of disease stage may allow the impact of existing and novel therapies to be assessed in the real-world setting. We present a dynamic progression model tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bca195d9a8dc0a111c8415d503a629b
https://doi.org/10.1200/jco.2020.38.15_suppl.e19144

Zobrazit plný text záznamu

Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry

Autor: Waleed Shalaby, Sarah Fleming, Arlene O. Siefker-Radtke, Frida Schain, Gary D. Steinberg, Roger Henriksson, Nurgul Batyrbekova, Thomas Powles, Joaquim Bellmunt

Publikováno v: Journal of Clinical Oncology. 38:5026-5026

5026 Background: To investigate the clinical and economic disease burden for patients (pts) with non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer (MIBC), and metastatic urothelial carcinoma (mUC) using a Swedish bladder canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a185d7c04b28fe2d65ef2865f372ac73
https://doi.org/10.1200/jco.2020.38.15_suppl.5026

Zobrazit plný text záznamu

Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)

Autor: M J Pontes Valero, George Wang, Scott Maul, Waleed Shalaby, Tracy McGowan, Bradley J. Monk, Spyros Triantos, Robert L. Coleman, Thomas J. Herzog

Publikováno v: Annals of Oncology. 30:v420-v421

Background Retreatment with PLD in ROC has raised potential concerns of increased toxicity and diminished response rates. This subgroup analysis examined the safety and efficacy of platinum-sensitive patients (pts) with prior PLD therapy who particip

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6dac1a7cef59ba0cb790f81dcd3964a
https://doi.org/10.1093/annonc/mdz250.038

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání